Phil Boyd BSc PhD ACMA FRSB
Phil is a qualified management accountant and currently acts as Chief Financial Officer (CFO) for
private life science companies Enterprise Therapeutics Ltd, Caldan Therapeutics Ltd and IGEM
Therapeutics Ltd. He was formerly CFO of Syntaxin Ltd from 2007 through to its acquisition by Ipsen
in 2013, CFO of Tiziana Lifesciences plc from 2014 to 2015, taking it through its IPO in April 2014, and
CFO of Oxford BioDynamics plc from 2015 to 2016 in preparation for its IPO in December 2016.
Prior
to this he was UK Finance Director of Evotec and Finance Director at Cambridge Discovery
Chemistry, and a management consultant with PwC. He is a past chair of the finance committee of
the BioIndustry Association (BIA) and was a non executive director of OBN (UK) Ltd. He has a BSc in
Biotechnology and a PhD in Genetics from Leeds University.